NZ247068A - Benzofuranylmethylthiazolidinedione derivatives and medicaments. - Google Patents
Benzofuranylmethylthiazolidinedione derivatives and medicaments.Info
- Publication number
- NZ247068A NZ247068A NZ247068A NZ24706893A NZ247068A NZ 247068 A NZ247068 A NZ 247068A NZ 247068 A NZ247068 A NZ 247068A NZ 24706893 A NZ24706893 A NZ 24706893A NZ 247068 A NZ247068 A NZ 247068A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- compound
- compounds
- thiazolidinedione
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
New Zealand Paient Spedficaiion for Paient Number £47068
24 7 0 6 8
I ...
CO.h^tUiO C pDC .iiC"!, ^11 : . 5.^,^$%., Pf^oc-;
Publication C:l.: P.O. Joiirnr!,
2 6 JAN 1994
..rsaw
EI ^ T^- n.* r * r> ^
Is M' Q L' If Q a "J H&s ^
NEW ZEALAND -JHJ!:lTrNT OFFICE
PATENTS ACT, 1953 ~ 5 MAR 1993
No.: ( Received
— Date:
n , COMPLETE SPECIFICATION nn jAcfi |\)gW Z^ffhAZo^PMftPlortZ CoHPo\JU-tO$ rKcfeSS fo£
, on ftePwM-fenm ritfMACzufiLftu 'coMfcsfo/tf ^7* Qx>\r(AmtJ(k ifjfeM
We, ADIR ET COMPAGNIE, a French body corporate, of 1 rue Carle Hebert, F-92415 Courbevoie, Cedex, France,
hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:-
(followed by page la)
- ICK-
24 7 0
The present invention relates to new 2,4-thiazolidinedione compounds, to a process for preparing them and to pharmaceutical compositions containing them.
Many 2,4-thiazolidinedione compounds are already described in the prior art as antidiabetic agents, for example in Patents EP-A-356,214 or WO-A-86/07056.
Patent EP-A-299,620 mentions benzofuranylmethyl- 2,4-thiazolidinedione compounds substituted with phenyl or substituted phenyl, pyridyl or substituted pyridyl and oxazolyl or substituted oxazolyl groups.
In Patent W0-A-91/I2003, a description is given of thiazolidinedione compounds which are known as antidiabetic agents and used for their antihypertensive property in insulin-resistant subjects.
The compounds of the present invention, apart from being new, differ from the other 2,4-thiazolidinedione compounds in the intensity of their pharmacological properties.
In effect, insulin resistance and deficiency in insulin secretion are the factors responsible for the glucose intolerance observed in patients having non- insulin-dependent diabetes.
The therapies currently available enable the deficiency in insulin secretion to be substantially corrected without necessarily improving the sensitivity of the peripheral tissues (muscles, adipose tissue) to insulin.
Compounds belonging to the 2,4-thiazolidinedione structure are capable of causing a drop in blood sugar level and of improving glucose tolerance in models of non-insulin-dependent diabetes without causing an increase in insulin secretion. Our compounds possess the advantage of being especially potent, more particularly in comparison to ciglitazone, a reference compound belonging to this chemical structure and whose efficacy remains low.
Thus, the compounds of the invention may be used in the treatment of non-insulinopenic diabetic states, enabling better control of the blood sugar level to be obtained while the circulating insulin level decreases. Prevention of this relative hyperinsulinemia, associated with a decrease in
24 7 0 f <
circulating triglycerides through the effect of these products, may contribute to a reduction in the risks of macroangiopathy.
These same compounds find a use, furthermore, in the treatment of hypertension in subjects exhibiting an insulin resistance, associated with other metabolic abnormalities or otherwise. More specifically, the present invention relates to the compounds of formula (I):
(I)
in which:
the broken line denotes the presence or absence of a double bond,
R represents one of the following groups A or B:
A :
in which:
Ri represents a hydrogen or halogen atom, a linear or branched (Ci~C6) alkyl group or a linear or branched (Ci~ Ce) alkoxy group,
X represents a CH radical or a nitrogen atom,
Y represents an NH radical or an oxygen or sulfur atom, and their isomers, enantiomurs and epimers as well as their addition salts with a pharmaceutically acceptable acid. The invention also encompasses the process for preparing the compounds of formula (I), wherein a compound of formula (II):
Hal
(II)
in which:
R is defined as in the formula (I),
Hal represents a chlorine or bromine atom,
is reacted with 5-bromosalicylaldehyde in the presence of an alkali metal salt, for example potassium carbonate, to give (III) :
0
(III)
where R is as described in (II), which, when subjected to the action of triethylsilane, is reduced to (IV):
(IV)
in which formula R is as described above,
which is converted to a compound of formula (V) with cuprous cyanide:
(V)
where R is as described above, to give, by reaction with an aluminum/nickel amalgam in the presence of acid such as, for example, trifluoroacetic acid, the compound of formula (VI), these last two steps being described by R.L. Dow et al. (J. Med. Chem., 34' (1988), 1538-1544):
CHO
(VI)
in which R has the same meaning as above, which compound (VI) is condensed with 2,4-thiazolidinedione in the presence of a base such as piperidine so as to obtain the compound (la), a special case of the compounds of formula (I):
4
0
R
I I / \
.N-H
(la)
0
where R is as described above, which, on catalytic hydrogenation, yields the product (lb), a special case of the compounds of the formula (I):
where R is as described above,
which compounds of formulae (la) and (lb) are purified, where appropriate, according to a standard purification technique, and the isomers of which are separated, if so desired, by a standard separation technique, and which are converted, if necessary, to their addition salts with a pharmaceutically acceptable acid.
The compounds of formula (I) possess very advantageous pharmacological properties. In effect, thiazolidinedione compounds are generally inactive in vitro and in normoglycemic animals not exhibiting an abnormality of glucose tolerance. The pharmacological study of the compounds of the invention is hence carried out:
in a model of non-insulin-dependent diabetes (NIDDM): the ob/ob mouse, and in a model of decreased glucose tolerance associated with hyperinsulinemia and hyperlipidemia: the Zucker FaPa rat. The results obtained in these tests show that the compounds of the invention permit control of the blood sugar level while the triglyceride and circulating insulin levels decrease. In addition to these pharmacological properties relating to hyperinsulinemia, the compounds of formula (I), though devoid of intrinsic hypotensive activity, decrease arterial blood pressure in insulin-resistant subjects and, as a result, may
R
(lb)
0
24 7 0 6 8
be used in therapy in the treatment of hypertension associated with insulin-resistance states and of other metabolic disorders such as, for example, obesity, dyslipidemia, hyperinsulinemia, and the like, which constitute considerable 5 cardiovascular risk factors (coronary disease,
macroangiopathy, and the like).
The subject of the present invention is also pharmaceutical compositions containing as active principle at least one compound of formula (I) or one of its physiological tolerable 10 salts, alone or in combination with one or more pharmaceutically suitable excipients.
The pharmaceutical compositions of the invention thereby obtained are advantageously presented in forms suitable for oral, parenteral or nasal administration, such as, for 15 example, tablets (simple or sugar-coated), sublingual tablets, hard gelatin capsules, troches, as well as in the form of suppositories, creams, ointments, skin gels, and the like. The appropriate dosage varies according to the patient's age and weight, the nature and severity of the disorder and the 20 administration route, and according to the nature of associated treatments. Generally speaking, the dosage ranges from 50 to 1000 mg of active principle of the invention, taken ^ in 1 to 3 doses per 24 hours.
The examples which follow illustrate the present invention 25 without, however, limiting it in any way. The starting materials are known, or are prepared according to standard procedures from known starting materials.
•
EXAMPLE 1 : 5 - [ 2 - ( 2-Naph t hy lme t hy 1 ) - 5 - be n z o f u r a n v 1 -methylene]-2,4-thiazolidinedione
First step : 2-(2-Naphthoyl)-5-bromobenzofuran
186 g (0.74 mol) of 2-bromo-2'-acetonaphthone, 150 g (0.74 mol) of 5-bromosalicylaldehyde and 103 g (0.74 mol) of potassium carbonate are mixed in 3.5 liters of methyl cyanide; the mixture is then brought to reflux overnight. The mixture
24 70"
is cooled to 0°C and then filtered to give 220 g of a brown solid, which is washed and dried.
Melting point : 158-159°C
Second step : 2-(2-Naphthylmethyl)-5-bromobenzofuran
220 g (0.63 mol) of product obtained above are added to 1.5 liters of trifluoroacetic acid and the mixture is cooled to 0°C. 220 ml (1.38 mol) of triethylsilane are added dropwise and the temperature is maintained for 2 hours at 0°C.
After evaporation of the trifluoroacetic acid, the residue is 10 taken up with ethyl acetate, and the organic phase is washed with water and then with saturated sodium chloride solution before being dried over magnesium sulfate. After evaporation of the solvent and purification on a silica column (eluant: cyclohexane/methylene chloride, 95:5), 75 g of expected 15 product are obtained.
Melting point : 98-100°C
Third step : 2-(2-Naphthylmethyl )-5-cvanobenzofuran
75 g (0.22 mol) of product obtained in the second step are added at room temperature to 40 g (0.44 mol) of cuprous 20 cyanide in 620 ml of dimethylformamide. The mixture is brought to 150°C for 48 hours; 20 g (0.22 mol) of cuprous cyanide are then added, and the mixture is again brought to 150°C for 60 hours.
When it has returned to room temperature, the reaction mixture 25 is poured into 300 ml of concentrated ammonia solution,
producing a blue coloration. After extraction with ethyl acetate, drying over magnesium sulfate and evaporation of the solvents, 60 g of a black oil are obtained. Purification on a silica column gives the expected product in the form of a 30 white solid.
Melting point : 202-203°C
Fourth step : 2-(2-Naphthylmethyl)-5-formylbenzofurari
21 g (74.2 mmol) of the product of the third step are introduced at room temperature into a round-bottomed flask containing 22.3 g of an aluminum/nickel amalgam in 220 ml of 70 % formic acid. The mixture is brought to reflux for 2 hours 30 minutes. After returning to room temperature, the reaction mixture is filtered and the solid residues are washed with 70 % formic acid.
The filtrate is extracted with ethyl acetate and the Ni/Al amalgam taken up several times with boiling ethyl acetate. The organic phases are washed with 4N sodium hydroxide solution until the pH reaches a constant value of 12. After washing with water, these organic phases are dried and evaporated to obtain 19.7 g of the expected product.
Melting point : 97-101°C
Fifth step : 5-[2-(2-Naphthylmethyl)-5-benzofuranyl-methylene]-2,4-thiazolidinedione
19.7 g (68.8 mmol) of the aldehyde obtained in the fourth step is brought into contact at room temperature with 8.1 g (69.2 mmol) of 2,4-thiazolidinedione and 5 ml of piperidine in 650 ml of absolute ethanol. The mixture is brought to reflux overnight and then cooled to room temperature. The solvent is evaporated off and a thick oil is obtained. The latter is taken up with isopropanol, in which the oil precipitates. The solid obtained (7.3 g) is filtered off and then dried.
Melting point : 210°C
EXAMPLE 2 : 5-[2-(2-Naphthylmethyl)-5-benzofuranylmethy1 ] -
2,4-thiazolidinedione
.5 g (14.3 mmol) of compound obtained in Example 1 are introduced into an autoclave at room temperature with 5 g of
palladium (in a 10 % dispersion in charcoal) in 80 ml of tetrahydrofuran. The autoclave is pressurized to 60 kg and reaction is performed at. 60°C for 2 days. After purification on a silica column and evaporation of the solvents, the solid is washed with ether, and 530 mg of white product are obtained.
Melting point : 151-153°C Elementary microanalysis :
C % H % N % S %
calculated 71.30 4.42 3.61 8.28
found 71.12 4.43 3.95 8.05
EXAMPLE 3 : 5 - [ 2- ( 2-Qu i no 1 y 1 me t hy 1) - 5 -b e n z o f u r a ny 1 -methylene]-2,4-thiazolidinedione
The product is prepared according to the same procedure as that described for Example 1, the first step in this case being a reaction between 5-bromosalicylaldehyde and bromomethyl 2-quinolyl ketone.
EXAMPLE 4 : 5 - [ 2 - ( 2 - B e n z o f u r a n y 1 m e t h y 1 ) - 5 - b e n z o -furanylmethylene]-2,4-thiazolidinedione
This compound is prepared according to the procedure in Example 1, using bromomethyl 2-benzofuranyl ketone as starting material.
EXAMPLE 5 : 5-[2-(-Indolylmethyl)-5-benzofuranylmethylene ]-2,4-thiazolidinedione
Preparation process identical to that of Example 1, using bromomethyl 2-indolyl ketone as starting material.
EXAMPLE 6 : 5-[2-(2-Benzo[b]thienylmethy 1)-5-benzo-furanylmethylene]-2,4-thiazolidinedione
247068
This compound is prepared according to the procedure of Example 1, using bromomethyl 2-benzo[b]thienyl ketone as starting material.
EXAMPLE 7 : 5-[2-(l-Naphthylmethyl)-5-benzofuranyl-methylene]-2,4-thiazolidinedione
Preparation process identical to that of Example 1, the starting material being bromomethyl-l-naphthyl ketone.
Examples 8 to 12 below afford the hydrogenated products of the compounds of Examples 3 to 7 respectively. The hydrogenations are performed according to the procedure described in Example 2.
EXAMPLE 8 : 5-[2-(2-Quinolylmethyl)-5-benzofuranylmethyl ] -2,4-thiazolidinedione
Obtained by hydrogenation of the compound of Example 3.
EXAMPLE 9 : 5 - [ 2 - ( 2 - B e n z o f u r a n y 1 m e t h y 1 ) - 5 - b e n z o furanylmethyl]-2,4-thiazolidinedione
Obtained by hydrogenation of the compound of Example 4.
EXAMPLE 10 : 5-[ 2-(2-Indolylmethy1)-5-benzofuranylmethyl] 2,4-thiazolidinedione
Obtained by hydrogenation of the compound of Example 5.
EXAMPLE 11 : 5 - [ 2 - ( 2 - Ben z o [ b ] t h i e ny lme t h y 1 ) - 5-b e n z o -furanylmethyl]-2,4-thiazolidinedione
Obtained by hydrogenation of the compound of Example 6.
EXAMPLE 12 : 5-[2-(1-Naphthylmethyl)-5-benzofuranylmethyl ] -2,4-thiazolidinedione
Obtained by hydrogenation of the compound of Example 7.
EXAMPLES TJ AND 14 : Enan.tiomers of example 2
EXAMPLE 13 : 5-[2-(2-Naphtylmethyl)-5-benzofuranylmethyl]-
2,4-thiazolidinedione, isomer a
EXAMPLE 14 : 5-[2-(2-Naphtylmethyl)-5-benzofuranylmethyl]-
2,4-thiazolidinedione, isomer 0
Isomers a and p of compound of example 2 have been separated by chiral chromatography under following conditions :
Column : stainless steel, L = 25 cm,
internal diameter : 4 mm Stationary phase : Chiralcel OJ (DIACEL)
Mobil phase : Ethanol/hexane (5/5)
Temperature : 35°C Flow rate : 0.9 ml/min Detection : UV - 254 nm Retention time : isomer a : 35 min isomer : 62 min
PHARMACOLOGICAL STUDY
EXAMPLE 15 : Study of the activity of the compounds of the invention on a model of non-insulin- dependent diabetes (NIDDM)
The animals (ob/ob mice) are treated every day for 4 days by oral administration of the compounds of the invention suspended in a 20 % solution of gum arabic.
Before and after treatment, that is to say at Do and at D5, the blood is sampled by puncture of the orbital sinus and the blood sugar level is determined.
Table 1 shows the doses of the different products to be administered in order to obtain the same hypoglycemic effect (base value 100).
(p\
I
as.
- Table 1 ; Doses producing the same hypoglycemic effect in ob/ob mice -
Pioglitazone
Englitazone
CS045
Ciglitazone
Example 2
Dose
(mg/kg/day) for 4 days
-20
150-200
50-100
-10
Hypoglycemic power
100
100
100
100
100
The study of a dose effect shows that the dose giving a 30 % decrease in the initial blood sugar level, ED30, for the compound of Example 2 is less than 0.1 mg/kg, whereas that for pioglitazone is between 5 and 10 mg/kg. The minimum active dose, MAD, showing a 10 to 15 % decrease in the blood sugar level is 0.1 mg/kg for the compound of Example 2, whereas it is 3 mg/kg for pioglitazone.
EXAMPLE 16 : Study of the activity of the compounds of the invention on a model of decreased glucose tolerance associated with hyperinsulinemia and hyperlipidemia
The animals (male Zucker Fa/Fa rats) are treated every day for 10 days by oral administration of the compounds of the invention, at a dose of 5 mg/kg/day, suspended in a 20 % solution of gum arabic. On the 11th day, the animals are sacrificed and the blood is collected in order to determine the blood sugar, plasma triglyceride and immunoreactive insulin levels. The animals are, moreover, weighed before and after treatment.
Under these conditions, the compounds of the invention have no influence on the circulating glucose level, but decrease the level of plasma triglycerides and free fatty acids as well as that of immunoreactive insulin. This activity is equal to or greater than that of other, reference thiazolidinedione compounds.
Claims (7)
- - 12 - 24 - Table 2 : Pharmacological study on male Zucker Fa/Fa rats - Dose (mg/kg/day) for 10 days Weight A W% Dn-Di0 Blood sugar level (%) Plasma insulin (%) TG (%) FFA (%) Control 0 100 100 100 100 100 Pioglitazone 5 219 103 61 44 52 Example 2 5 250 97 50 35 48 (TG = triglycerides ; FFA = free fatty acids) PHARMACEUTICAL COMPOSITION EXAMPLE 17 : Tablet : Preparation formula for 1000 tablets containing a 50 mg dose 5-[2-(2-Naphthylmethyl)-5-benzofuranylmethyl]- 2,4-thiazolidinedione 50 g Hydroxypropylcellulose 2 g Wheat starch 10 g Lactose 100 g Magnesium stearate 3 g Talc 3 g 13 WHATifiWE CLAIM IS 1. A compound of formula (I): r ,n — h 0 (I) 0 in which: - the broken line denotes the presence or absence of a double bond, R represents one of the following groups A or B: in which: - Ri represents a hydrogen or halogen atom, a linear or branched (Ci-Cg) alkyl group or a linear or branched (Ci~ C6) alkoxy group, - X represents a CH radical or a nitrogen atom, Y represents an NH radical or an oxygen or sulfur atom, and its isomers, enantiomers and epimers as well as its addition salts with a pharmaceutically acceptable acid.
- 2. A compound of formula (I) as claimed in claim 1, in which the group R represents a naphthyl radical, its isomers, enantiomers and epimers as well as its addition salts with a pharmaceutically acceptable acid.
- 3. The compound of formula (I) as claimed in claim 1, which is 5-[2-(2-naphthylmethyl)-5-benzofuranylmethyl]-2,4-thiazolidinedione, its enantiomers and epimers as well as its addition salts with a pharmaceutically acceptable acid. a : b : - 14 - 247068
- 4. A process for preparing a compound of formula (I)/ wherein a compound of formula (II): R-, 'Hal (II) in which: R is defined as in the formula (I), Hal represents a chlorine or bromine atom, is reacted with 5-bromosalicylaldehyde in the presence of an alkali metal salt, for example potassium carbonate, to give (III): Br (HI) where R is as described in (II), which, when subjected to the action of triethylsilane, is reduced to (IV): Br (IV) in which formula R is as described above, which is converted to a compound of formula (V) with cuprous cyanide: CN (V) where R is as described above, to give, by reaction with an aluminum/nickel amalgam in the presence of acid such as, for example, trifluoroacetic acid, the compound of formula (VI): CHO (VI) - 15 - vV (la) — H % P, in which R has the same meaning as above, which compound (VI) is condensed with 2,4-thia2olidinedione in the presence of a base such as piperidine so as to obtain the compound (la), a special case of the compounds of formula (I): .0 where R is as described above, which, on catalytic hydrogenation, yields the product (lb), a special case of the compounds of the formula (I): .0 (lb) where R is as described above, which compounds of formulae (la) and (lb) are purified, where appropriate, according to a standard purification technique, and the isomers of which are separated, if so desired, by a standard separation technique, and which are converted, if necessary, to their addition salts with a pharmaceutically acceptable acid.
- 5. A pharmaceutical composition containing as active principle at least one compound as claimed in any one of claims 1 to 3, alone or in combination with one or more pharmaceutically acceptable, non-toxic, inert vehicles.
- 6. The pharmaceutical composition as claimed in claim 5, containing at least one active principle as claimed in any one of claims 1 to 3, which is useful in the treatment of non-insulinopenic diabetes, associated with hypertension or otherwise.
- 7. A compound of formula (I) as defined in claim 1 substantially as herein described with reference to the examples' i ;*.Z. FAT' -5 : f\M ET COMMQMl Byte/ their authorised Agents AI PARK & SON. « I RECEIVED
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9202671A FR2688220A1 (en) | 1992-03-06 | 1992-03-06 | NOVEL THIAZOLIDINE-2,4-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ247068A true NZ247068A (en) | 1994-01-26 |
Family
ID=9427406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ247068A NZ247068A (en) | 1992-03-06 | 1993-03-05 | Benzofuranylmethylthiazolidinedione derivatives and medicaments. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0559571A1 (en) |
| JP (1) | JPH069629A (en) |
| AU (1) | AU654899B2 (en) |
| CA (1) | CA2091127A1 (en) |
| FR (1) | FR2688220A1 (en) |
| NZ (1) | NZ247068A (en) |
| ZA (1) | ZA931593B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4317320A1 (en) * | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | New thiazolidinediones and medicines containing them |
| ATE376829T1 (en) * | 1993-09-15 | 2007-11-15 | Daiichi Sankyo Co Ltd | USE OF THIAZOLIDINDIONES TO PREVENT OR DELAY THE OCCURMENT OF NONINSULIN DEPENDENT DIABETES MELLITUS (NIDDM) |
| CA2171702A1 (en) * | 1995-03-14 | 1996-09-15 | Takashi Sohda | Benzofuran compounds and their use |
| DE19711616A1 (en) | 1997-03-20 | 1998-09-24 | Boehringer Mannheim Gmbh | Improved process for the preparation of thiazolidinediones |
| WO1998052946A1 (en) * | 1997-12-02 | 1998-11-26 | Dr. Reddy's Research Foundation | Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension |
| CZ20003960A3 (en) * | 1998-05-04 | 2002-04-17 | Zentaris Ag | Indole derivatives and their use for treating malignant and other diseases induced by pathological proliferation of cells |
| WO2000018746A1 (en) * | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
| US6756360B1 (en) | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| US7563774B2 (en) | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703052A (en) * | 1985-05-21 | 1987-10-27 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
| GB8713861D0 (en) * | 1987-06-13 | 1987-07-15 | Beecham Group Plc | Compounds |
-
1992
- 1992-03-06 FR FR9202671A patent/FR2688220A1/en active Granted
-
1993
- 1993-03-05 EP EP93400568A patent/EP0559571A1/en not_active Withdrawn
- 1993-03-05 ZA ZA931593A patent/ZA931593B/en unknown
- 1993-03-05 CA CA002091127A patent/CA2091127A1/en not_active Abandoned
- 1993-03-05 NZ NZ247068A patent/NZ247068A/en unknown
- 1993-03-05 AU AU34008/93A patent/AU654899B2/en not_active Ceased
- 1993-03-05 JP JP5045192A patent/JPH069629A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0559571A1 (en) | 1993-09-08 |
| AU654899B2 (en) | 1994-11-24 |
| CA2091127A1 (en) | 1993-09-07 |
| JPH069629A (en) | 1994-01-18 |
| FR2688220B1 (en) | 1995-06-02 |
| AU3400893A (en) | 1993-09-09 |
| FR2688220A1 (en) | 1993-09-10 |
| ZA931593B (en) | 1993-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0528734B1 (en) | Thiazolidin-2,4-dione derivatives, process for their preparation and pharmaceutical compositions containing them | |
| ZA200510294B (en) | Hexahydropyridoisoquinolines as DPP-IV inhibitors | |
| AU654899B2 (en) | New 2,4-thiazolidinedione compounds, process for preparing them and pharmaceutical compositios containing them | |
| JP2650038B2 (en) | Pyrrolitidine compounds and uses thereof | |
| Cannon et al. | Congeners of the. beta. conformer of dopamine derived from cis-and trans-octahydrobenzo [f] quinoline and trans-octahydrobenzo [g] quinoline | |
| CN1989090B (en) | Cis-1,2-substituted diphenyl ethylene derivatives and its use in preparing medine for treating and/or preventing diabetes | |
| EP0543713B1 (en) | Ethanolamine benzoate derivatives, process for their preparation and pharmaceutical compositions containing them | |
| US4134991A (en) | Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid | |
| EP1098891A1 (en) | Polycyclic thiazolidin-2-ylidene amines, method for the production and use thereof as medicaments | |
| JP2001514632A (en) | New heterocyclic compounds | |
| WO2000051579A2 (en) | Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity | |
| DK166147B (en) | N-OE6-METHOXY-5- (PERFLOURALKYL) -1-NAPHTHOYLAA-N-METHYLGYLINES AND THEIR THIONAPHTHOYLANALOGUE, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| CA2108064C (en) | Thiazolidine dione compounds, process for preparing same and pharmaceutical compositions containing same | |
| EP3964514A1 (en) | Ginkgolide b derivative and salt thereof, preparation method therefor and use thereof | |
| JPS6011898B2 (en) | New benzenesulfonamide derivatives, their production methods and pharmaceutical compositions containing them | |
| CZ286649B6 (en) | 2-(Aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano/2,3-e/indol-8-one derivatives and pharmaceutical preparation in which they are comprised | |
| US5464859A (en) | Benzospiroalkene derivatives | |
| EP0430800B1 (en) | Substituted benzothiazolinones, process for their preparation and pharmaceutical compositions containing them | |
| WO2002016338A1 (en) | Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same | |
| US4349547A (en) | Suppressing obesity and over-secretion of insulin with 2-(α-hydroxy-m-trifluoromethylbenzyl)azetidine | |
| NZ199008A (en) | 2,3,3a,4,5,6-hexahydro-ih-indolo(3,2,1-de)(1,5)-naphthyridines | |
| EP0745597A2 (en) | Novel melatonergic indanyl piperazines or homopiperazines | |
| CZ20023718A3 (en) | Optically active 2-aminotetraline derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
| LU80712A1 (en) | POLYFLUOROHYDROXYISOPROPYL CARBOSTYRIL TRICYCLIC ANTIHYPERTENSITIVE COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| NZ200643A (en) | 2-amino-3-(substituted phenyl)-3-butenoic acid derivatives and pharmaceutical compositions |